Elliot Favus Net Worth

The estimated Net Worth of Elliot Favus is at least $838 Mille dollars as of 21 May 2021. Mr. Favus owns over 145,000 units of Anavex Life Sciences stock worth over $743,850 and over the last 10 years he sold AVXL stock worth over $0. In addition, he makes $93,871 as Independent Director at Anavex Life Sciences.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Favus AVXL stock SEC Form 4 insiders trading

Elliot has made over 2 trades of the Anavex Life Sciences stock since 2021, according to the Form 4 filled with the SEC. Most recently he exercised 145,000 units of AVXL stock worth $281,300 on 21 May 2021.

The largest trade he's ever made was exercising 145,500 units of Anavex Life Sciences stock on 24 February 2021 worth over $445,230. On average, Elliot trades about 32,278 units every 10 days since 2015. As of 21 May 2021 he still owns at least 145,000 units of Anavex Life Sciences stock.

You can see the complete history of Mr. Favus stock trades at the bottom of the page.

Elliot Favus biography

Elliot J. Favus M.D. serves as Independent Director of the Company. He has been a healthcare equity research analyst on Wall Street since 2006, starting at Lazard Capital Markets and subsequently at Och-Ziff Capital Management Group. Prior to working on Wall Street, Dr. Favus was an Instructor in medicine at Mount Sinai School of Medicine in New York. He attended the University of Michigan (BA, 1996), the University of Chicago Pritzker School of Medicine (MD, 2001) and the NYU-Bellevue Hospital Internal Medicine Residency Program (2004). He is board-certified in Internal Medicine (2004) and has 10 years of basic science laboratory experience working on human genetics projects at Harvard Medical School, the University of Chicago and the University of Pittsburgh.

What is the salary of Elliot Favus?

As the Independent Director of Anavex Life Sciences, the total compensation of Elliot Favus at Anavex Life Sciences is $93,871. There are 5 executives at Anavex Life Sciences getting paid more, with Christopher Missling having the highest compensation of $3,380,040.

How old is Elliot Favus?

Elliot Favus is 45, he's been the Independent Director of Anavex Life Sciences since 2014. There are 7 older and 2 younger executives at Anavex Life Sciences. The oldest executive at Anavex Life Sciences Corporation is Stephan Toutain, 55, who is the Chief Operating Officer.

What's Elliot Favus's mailing address?

Elliot's mailing address filed with the SEC is 51 W 52nd St 7TH FLOOR, New York, NY 10019, USA.

Insiders trading at Anavex Life Sciences

Over the last 18 years, insiders at Anavex Life Sciences have traded over $5,238,591 worth of Anavex Life Sciences stock and bought 135,460 units worth $453,776 . The most active insiders traders include Athanasios Skarpelos, Christopher U Missling e Elliot Favus. On average, Anavex Life Sciences executives and independent directors trade stock every 99 days with the average trade being worth of $335,876. The most recent stock trade was executed by Peter D.O. Donhauser on 14 June 2024, trading 2,835 units of AVXL stock currently worth $10,319.

What does Anavex Life Sciences do?

anavex life sciences corp. is a clinical stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodevelopmental and neurodegenerative diseases. anavex is currently in a phase 2a trial for alzheimer's disease (ad) with lead therapeutic, anavex 2-73, an orally available small molecule targeting protein misfolding and cellular stress through activating the sigma-1 receptor. part a topline data of our ongoing phase 2a trial demonstrate a favorable safety, bioavailability, dose-response curve and tolerability/risk profile. anavex 2-73 is a potential platform drug showing encouraging preclinical data rare neurodevelopmental disease: rett syndrome, as well is in epilepsy and multiple sclerosis (ms). in 2015, the company was awarded a research by the michael j. fox foundation (mjff) to study anavex 2-73 for the treatment of parkinson’s disease. headquartered in new york, anavex is an american publicly traded corporation quoted as avxl.

Complete history of Mr. Favus stock trades at Anavex Life Sciences

Anavex Life Sciences executives and stock owners

Anavex Life Sciences executives and other stock owners filed with the SEC include:

• Christopher Missling,
  President, Chief Executive Officer, Secretary, Director
• Dr. Christopher U. Missling,
  Chairman, Pres, CEO & Sec.
• Sandra Boenisch,
  Principal Financial Officer, Treasurer
• Sandra Boenisch CPA, CPA, CGA,
  Principal Financial Officer & Treasurer
• Claus van der Velden,
  Independent Director
• Steffen Thomas,
  Independent Director
• Athanasios Skarpelos,
  Independent Director
• Elliot Favus,
  Independent Director
• Peter Donhauser,
  Independent Director
• Dr. Adebayo Laniyonu Ph.D.,
  Sr. VP of Nonclinical Devel.
• Clint Tomlinson,
  VP of Corp.
• Dr. Walter E. Kaufmann M.D.,
  Chief Medical Officer
• Dr. Emmanuel O. Fadiran RPh, Ph.D.,
  Sr. VP of Regulatory Affairs
• Stephan Toutain,
  Chief Operating Officer
• Bernd Metzner,
  Director
• Jiong Ma,
  Director
• Cameron Durrant,
  Director
• Harvey Lalach,
  President, CFO
• Alison E. Ayers,
  Director
• David L. Tousley,
  Director
• George F Tidmarsh,
  Executive Director
• Panos Kontzalis,
  CEO
• George Kalkanis,
  VP Strategic Planning
• Angela Vernadaki,
  VP Business Development